Esperion Therapeutics (ESPR) Amortization of Deferred Charges (2012 - 2026)

Esperion Therapeutics has reported Amortization of Deferred Charges for 13 years, with the latest figure at $589000.0 in Q1 2026.

• For the quarter ending Q1 2026, Amortization of Deferred Charges fell 15.74% year-over-year to $589000.0; the trailing twelve-month figure through Mar 2026 stood at $19.4 million (up 1115.13% YoY), and the FY2025 full-year result was $3.0 million, changed N/A from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $589000.0, down from $641000.0 in the prior quarter.
• The five-year high for Amortization of Deferred Charges was $9.1 million in Q2 2025, with the low at -$1.3 million in Q4 2023.
• Historically, Amortization of Deferred Charges has averaged $1.4 million across 5 years, with a median of $424500.0 in 2023.
• Annual changes were most pronounced in 2023 — Amortization of Deferred Charges slumped 405.8% — and 2025, when it jumped 2175.0%.
• Esperion Therapeutics' Amortization of Deferred Charges stood at $414000.0 in 2022, then tumbled by 405.8% to -$1.3 million in 2023, then soared by 131.6% to $400000.0 in 2024, then soared by 60.25% to $641000.0 in 2025, then slipped by 8.11% to $589000.0 in 2026.
• The last three Amortization of Deferred Charges figures came in at $589000.0 (Q1 2026), $641000.0 (Q4 2025), and $9.1 million (Q3 2025), per Business Quant data.